Left Ventricular Ejection Fraction clinical trials at University of California Health
2 in progress, 1 open to eligible people
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
open to eligible people ages 18-85
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
at UC Davis UC Irvine UCSF
Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure
Sorry, not currently recruiting here
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether BI 690517 in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: - BI 690517 and empagliflozin group: participants take BI 690517 and empagliflozin as tablets once a day. - Placebo and empagliflozin group: participants take placebo and empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until we have enough data to see if the treatment is working.
at UC Irvine
Last updated: